(vianews) - contextvision (contx.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| contextvision (contx.ol) | kr7.68 | 3.46% | 61.1% |
| vetoquinol (veto.pa) | €102.80 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. contextvision (contx.ol)
3.46% forward dividend yield and 61.1% return on equity
contextvision ab (publ), a medical technology software company, provides image analysis and imaging for medical systems in asia, europe, and the united states. the company offers image enhancement software for 2d/3d/4d ultrasound, radiography, magnetic resonance imaging (mri), and veterinary. its products include rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; rivent mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and rivent 3d, an image enhancement product for 3d ultrasound. the company also provides altumira/altumira plus, a platform for digital radiography; and orthopedic package for orthopedic imaging. in addition, it offers gopview mri2plus, an image enhancement solution for mri. the company was founded in 1983 and is headquartered in stockholm, sweden.
earnings per share
as for profitability, contextvision has a trailing twelve months eps of kr0.48.
pe ratio
contextvision has a trailing twelve months price to earnings ratio of 16. meaning, the purchaser of the share is investing kr16 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.
earnings before interest, taxes, depreciation, and amortization
contextvision's ebitda is 49.39.
volatility
contextvision's last week, last month's, and last quarter's current intraday variation average was a negative 0.07%, a positive 0.35%, and a positive 2.03%.
contextvision's highest amplitude of average volatility was 1.12% (last week), 1.73% (last month), and 2.03% (last quarter).
yearly top and bottom value
contextvision's stock is valued at kr7.68 at 16:30 est, below its 52-week low of kr7.80.
sales growth
contextvision's sales growth for the current quarter is 29.8%.
more news about contextvision.
2. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.68. meaning, the purchaser of the share is investing €20.68 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
revenue growth
year-on-year quarterly revenue growth declined by 5.4%, now sitting on 525.26m for the twelve trailing months.
volume
today's last reported volume for vetoquinol is 2241 which is 8.34% below its average volume of 2445.
yearly top and bottom value
vetoquinol's stock is valued at €102.80 at 16:30 est, above its 52-week high of €98.60.
volatility
vetoquinol's last week, last month's, and last quarter's current intraday variation average was 1.91%, 0.59%, and 1.44%.
vetoquinol's highest amplitude of average volatility was 2.01% (last week), 1.43% (last month), and 1.44% (last quarter).
more news about vetoquinol.